Impact of PIK3CA mutation status on immune marker response and pCR in the WSG-ADAPT HER2+/HR+ phase II trial.

被引：1
|
作者：
Harbeck, Nadia
Nitz, Ulrike
Christgen, Matthias
Kates, Ronald E.
Braun, Michael Wilhelm
Kummel, Sherko
Schumacher, Claudia
Potenberg, Jochem
Malter, Wolfram
Augustin, Doris
Aktas, Bahriye
Forstbauer, Helmut
Tio, Joke
Kleine-Tebbe, Anke
Liedtke, Cornelia
de Haas, Sanne
Deurloo, Regula
Wuerstlein, Rachel
Kreipe, Hans Heinrich
Gluz, Oleg
机构：
[1] Univ Munchen LMU, Brustzentrum, Munich, Germany
[2] Evangel Hosp Bethesda, Breast Canc Niederrhein, Monchengladbach, Germany
[3] Hannover Med Sch, Hannover, Germany
[4] West German Study Grp, Monchengladbach, Germany
[5] Rotkreuzklinikum, Munich, Germany
[6] Kliniken Essen Mitte, Essen, Germany
[7] St Elisabeth Hosp Koln Hohenlind, Cologne, Germany
[8] Waldkrankenhaus Spandau, Dept Hematol, Berlin, Germany
[9] Univ Hosp Cologne, Dept Obstet & Gynecol, Cologne, Germany
[10] Klinikum Deggendorf, Deggendorf, Germany
[11] Univ Hosp Leipzig, Univ Hosp Essen, Essen, Germany
[12] Practice Network Hematol Oncol, Troisdorf, Germany
[13] Univ Hosp Muenster, Dept Gynecol & Obstet, Munster, Germany
[14] DRK Kliniken Berlin Kopenick, Berlin, Germany
[15] Charite Univ Med Berlin, Berlin, Germany
[16] F Hoffmann La Roche Ltd, Basel, Switzerland
[17] Ludwig Maximilians Univ Munchen, Munich, Germany
[18] Breast Ctr Niederrhein, Monchengladbach, Germany
[19] Univ Clin Cologne, Monchengladbach, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.572
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
572
引用
收藏
页数：1
相关论文
共 50 条
  • [21] De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel
    Nitz, U. A.
    Gluz, O.
    Christgen, M.
    Grischke, E. -M
    Augustin, D.
    Kuemmel, S.
    Braun, M.
    Potenberg, J.
    Kohls, A.
    Krauss, K.
    Stefek, A.
    Schumacher, C.
    Forstbauer, H.
    Reimer, T.
    Fischer, H.
    Liedtke, C.
    Wuerstlein, R.
    Schumacher, J.
    Kates, R.
    Kreipe, H.
    Harbeck, N.
    ANNALS OF ONCOLOGY, 2017, 28 (11) : 2768 - 2772
  • [22] PIK3CA mutation status, progression and survival in advanced HR + /HER2- breast cancer: a meta-analysis of published clinical trials
    Mirko Fillbrunn
    James Signorovitch
    Fabrice André
    Iris Wang
    Ines Lorenzo
    Antonia Ridolfi
    Jinhee Park
    Akanksha Dua
    Hope S. Rugo
    BMC Cancer, 22
  • [23] PIK3CA mutation status, progression and survival in advanced HR +/HER2-breast cancer: a meta-analysis of published clinical trials
    Fillbrunn, Mirko
    Signorovitch, James
    Andre, Fabrice
    Wang, Iris
    Lorenzo, Ines
    Ridolfi, Antonia
    Park, Jinhee
    Dua, Akanksha
    Rugo, Hope S.
    BMC CANCER, 2022, 22 (01)
  • [24] PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype
    Guarneri, Valentina
    Dieci, Maria Vittoria
    Bisagni, Giancarlo
    Brandes, Alba A.
    Frassoldati, Antonio
    Cavanna, Luigi
    Musolino, Antonino
    Giotta, Francesco
    Rimanti, Anita
    Garrone, Ornella
    Bertone, Elena
    Cagossi, Katia
    Nanni, Oriana
    Piacentini, Federico
    Orvieto, Enrico
    Griguolo, Gaia
    Curtarello, Matteo
    Urso, Loredana
    Pare, Laia
    Chic, Nuria
    D'Amico, Roberto
    Prat, Aleix
    Conte, Pierfranco
    CLINICAL CANCER RESEARCH, 2020, 26 (22) : 5843 - 5851
  • [25] Treatment sequencing of HR+/HER2-metastatic breast cancer (mBC) patients based on PIK3CA alteration status - A retrospective analysis of a US clinicogenomics database
    Turner, Stuart J.
    Wang, Iris
    Park, Jinhee
    Kanakamedala, Hemanth
    Lorenzo, Ines
    CANCER RESEARCH, 2020, 80 (04)
  • [26] Phase Ib/II trial of copanlisib in combination with trastuzumab and pertuzumab after induction treatment of HER2 positive metastatic breast cancer with PIK3CA mutation or PTEN mutation
    Damodaran, Senthil
    Murthy, Rashmi K.
    Nusrat, Maliha
    Saigal, Babita
    Trager, Samantha C.
    Tripathy, Debu
    Meric-Bernstam, Funda
    CANCER RESEARCH, 2021, 81 (04)
  • [27] Predictive impact of biomarkers on pCR and survival after de-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs. trastuzumab+ET in HER2+/HR+ early breast cancer: WSG ADAPT TP trial
    Harbeck, N.
    Nitz, U.
    Christgen, M.
    Kuemmel, S.
    Braun, M.
    Biehl, C. M.
    Schumacher, C.
    Malter, W.
    Aktas, B.
    Forstbauer, H.
    Tio, J.
    Grischke, E-M.
    Kolberg-Liedtke, C.
    de Haas, S.
    Deurloo, R. J.
    Kates, R. E.
    Zu, C. Eulenburg
    Wuerstlein, R.
    Kreipe, H.
    Gluz, O.
    ANNALS OF ONCOLOGY, 2021, 32 : S1285 - S1285
  • [28] Concordance and clinical impact of ER, PR, HER2 expression by local and central immunohistochemistry versus RT-PCR in HR+/HER2-early breast cancer (EBC): Results from the ADAPT trial.
    Gluz, Oleg
    Christgen, Matthias
    Kuemmel, Sherko
    Eulenburg, Christine Zu
    Braun, Michael
    Aktas, Bahriye
    Luedtke-Heckenkamp, Kerstin
    Forstbauer, Helmut
    Grischke, Eva-Maria
    Schumacher, Claudia
    Krauss, Katja
    Thill, Marc
    Warm, Mathias
    Graeser, Monika Karla
    Wuerstlein, Rachel
    Kates, Ronald E.
    Baehner, Frederick L.
    Nitz, Ulrike
    Kreipe, Hans Heinrich
    Harbeck, Nadia
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [29] PIK3CA mutation status in tumor tissue and ctDNA as a biomarker for PFS in patients with HR+, HER2-ABC treated with buparlisib or placebo plus fulvestrant: results from the BELLE-2 and BELLE-3 randomized studies
    Baselga, Jose
    Sellami, Dalila
    El-Hashimy, Mona
    Dharan, Bharani
    Wang, Amanda
    Scheuer, Nicolas
    Sankaran, Banu
    Di Leo, Angelo
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [30] A Phase II study of the safety and efficacy of alpelisib or buparlisib plus letrozole in neoadjuvant treatment of postmenopausal women with HR+/HER2-, PIK3CA mutant or wild-type breast cancer.
    Mayer, Ingrid A.
    Singer, Christian F.
    Fasching, Peter A.
    Holmes, Frankie Ann
    Gnant, Michael
    Estevez, Laura G.
    Campone, Mario
    Hubalek, Michael
    Wolff, Antonio C.
    Perez-Fidalgo, Jose Alejandro
    Winer, Eric P.
    Atalla-Vidam, Gena
    Kanwal, Charu
    Blumenstein, Lars
    Fretault, Nathalie
    Diaz-Padilla, Ivan
    Arteaga, Carlos L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345